Clinical Trial Search

Primary: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint — -10.3; -6.6 mmHg

Primary: The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal…

Primary: Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen — 86.12 Percentage of…

Primary: Change in Mean Trough Sitting Diastolic Blood Pressure — -11.16; -10.45 mm Hg — p=0.2648

Primary: Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 — 99.2; -12.7 mm Hg — p=<0.05

Primary: Change in Nocturnal Systolic Blood Pressure Level — -12.6; -17.5 mmHg

Primary: Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7 — -28.5; -37.0 mmHg — p=<0.0001

Primary: Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16 — -11.16; -9.13; -8.10; -5.66 mm Hg — p=<0.0001

Primary: Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg — -6.1; -7.1; -8.9 mm Hg — p=0.1187

Primary: Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy) — 38 Participants

Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg

Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) — -11.53; -10.98; -12.45; -3.69 mmHg

Primary: Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) — -9.1; -8.0 mmHg — p=0.205

Primary: Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP) — 163.9; 163.3; 140.9; 144.4 mmHg

Primary: Change in Resting vs. Peak Heart Rate Systolic Blood Pressure (SBP) From Baseline to Week 8 After a Missed Dose — 2.58; 8.26 mmHg

Primary: Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)…

Primary: Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood…

Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) — -31.37; -27.99; -30.77; -37.92 mmHg

Primary: Change in Trough Sitting Diastolic Blood Pressure (SiDBP)-Double-Blind Treatment Period — -12.1; -6.2 mmHg — p=<0.001

Primary: Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) — -8.7; -3.6 mmHg — p=<.001

Primary: DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean — -12.76; -23.82 mmHg

Primary: Mean Change of Diastolic Blood Pressure — -10.15; -7.19; -6.70 mmHg — p=<0.05

Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg

Primary: SBP — 130.2; 128.8 mm Hg

Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2

Primary: The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85 — 34.0; 59.2 Percent of participants — p=0.0158

Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8 — -8.01; -6.30 mmHg

Primary: dBP Change After 8 Weeks Phase A — -15.8; -18.9 mmHG — p=<0.0001

Primary: Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study — -9.13 mmHg

Primary: Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure. — -37.6; -38.2; -31.5 mmHg — p=<0.001